This is a working overview of Cardarine, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-06 and is reviewed periodically as new material appears.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Leucine is a branched-chain amino acid (BCAA) since it possesses an aliphatic side chain that is not linear. Racemic leucine had been subjected to circularly polarized synchrotron radiation to better understand the origin of biomolecular asymmetry. An enantiomeric enhancement of 2.6% had been induced, indicating a possible photochemical origin of biomolecules' homochirality.
Heseltine was seen as more interested in large than in small and medium-sized companies, and in 1992 was only with difficulty persuaded to refer Lloyds Bank's takeover bid for Midland Bank to the Office of Fair Trading.
Pea protein is a food product and protein supplement derived and extracted from yellow and green split peas, Pisum sativum. It can be used as a dietary supplement to increase an individual's protein or other nutrient intake, or as a substitute for other food products (e.g. the substitution of dairy milk by pea milk). As a powder, it is used as an ingredient in food manufacturing, such as a thickener, foaming agent, or an emulsifier. It is extracted in a powder form and can be processed and produced in different ways:
Sources: en.wikipedia.org
== Methods of detection == In a GC-O analysis, various methods are used to determine the odour contribution of a compound or the relative importance of each odorant. The methods can be categorised as (i) detection frequency, (ii) dilution to threshold and (iii) direct intensity.
The M80 Stiletto is an American prototype naval ship using advanced stealth technologies. The M80 was designed by the M Ship Company then built by Knight and Carver, as an experimental testbed ship for The Pentagon’s Office of Force Transformation. It is notable for its innovative pentamaran hull design and advanced carbon fiber composite construction. The multihull uses its width to gain stability. Its five slim hulls create virtually no bow wave, thus obviating the "hull speed' limitation of displacement craft. The Stiletto's "double-M hull" enables the craft to achieve a remarkably steady ride in rough seas at high speed. A disadvantage is that the five hulls give a large "wetted area", increasing drag.
Methamphetamine is another popular drug among distributors. Three common street names are "meth", "crank", and "ice". According to the Community Epidemiology Work Group, the number of clandestine methamphetamine laboratory incidents reported to the National Clandestine Laboratory Database decreased from 1999 to 2009. During this period, methamphetamine lab incidents increased in mid-western States (Illinois, Michigan, Missouri, and Ohio), and in Pennsylvania. In 2004, more lab incidents were reported in Missouri (2,788) and Illinois (1,058) than in California (764). In 2003, methamphetamine lab incidents reached new highs in Georgia (250), Minnesota (309), and Texas (677). There were only seven methamphetamine lab incidents reported in Hawaii in 2004, though nearly 59 percent of substance use treatment admissions (excluding alcohol) were for primary methamphetamine use during the first six months of 2004. As of 2007, Missouri leads the United States in drug-lab seizures, with 1,268 incidents reported. Often canine units are used for detecting rolling meth labs which can be concealed on large vehicles, or transported on something as small as a motorcycle. These labs are more difficult to detect than stationary ones, and can often be obscured among legal cargo in big trucks. Methamphetamine is sometimes used intravenously, placing users and their partners at risk for transmission of HIV and hepatitis C. "Meth" can also be inhaled, most commonly vaporized on aluminum foil or in a glass pipe. This method is reported to give "an unnatural high" and a "brief intense rush".
=== Co-Precipitation === Actinide isolation by co-precipitation is frequently used for samples of relatively large volumes to concentrate analytes and remove interferences. Actinide carriers include iron hydroxides, lanthanide fluorides/hydroxides, manganese dioxide, and a few other species.
Sources: en.wikipedia.org
I am ordering all carriers, including FedEx, Amazon, UPS and the Post Office, to search for and refuse all deliveries of fentanyl from China (or anywhere else!). Fentanyl kills 100,000 Americans a year. President Xi said this would stop – it didn't.
=== Immune dysregulation === MS usually begins when immune cells known as T cells and B cells erroneously attack the body's own nervous system by releasing signals that cause inflammation in brain and other neurological tissues. This is supported by the presence of certain antibodies (oligoclonal IgG bands) commonly found in the spinal fluid of people with MS. Although T cells have been considered to be the major contributors to the inflammatory demyelination occurring in MS, recent studies indicate that B cells also play a significant role in the pathogenesis of this disease.
One of the best examples of the special features caused by DNA encoding is the synthesis of the self-assembling library introduced by Mlecco et al. First, two sublibraries are synthesized. In one of the sublibraries BBs are attached to the 5’ end of an oligonucleotide containing a dimerization domain followed by the codes of the BBs. In the other sublibrary the BBs are attached to the 3’ end of the oligonucleotides also containing a dimerization domain and the codes of another set of BBs. The two sublibraries are mixed in equimolar quantities, heated to 70 °C then allowed to cool to room temperature, heterodimerize and form the self-assembling combinatorial library. One member of such two pharmacophore library is shown in the figure. In affinity screening, the two BBs of the pharmacophore may interact with the two adjacent binding sites of the target protein.
== References == Anderson, G.B., (1999). "Epidemiological features of chronic low back pain". The Lancet (1) 354 Langevin, H.M., Bouffard, N.A., Badger, G.J., Churchill, D.L., Howe, A.K., (2006). "Subcutaneous tissue fibroblasts cytoskeletal remodeling induced by acupuncture: evidence for a mechanotransduction-based mechanism". J Cell Physiol (3) 207 Langevin, H.M., Churchill, D.L., Cipolla, M.J., (2001). "Mechanical signalling through connective tissue: A mechanism for the therapeutic effect of acupuncture". FASEB J (1) 15
== History == GABA is the principal inhibitory neurotransmitter in mammalian brains. By the early 1970s, it was appreciated that there are two main classes of GABA receptors, GABAA and GABAB and also that baclofen was an agonist of GABAB receptors. Gabapentin was designed, synthesized, and tested in mice by researchers at the pharmaceutical company Goedecke AG in Freiburg, Germany (a subsidiary of Parke-Davis). It was meant to be a structural analog of the neurotransmitter GABA that could more easily cross the blood–brain barrier. It was first synthesized in 1974/75 and described in 1975 by Satzinger and Hartenstein. The first pharmacology findings published were sedating properties and prevention of seizures in mice evoked by the GABA antagonist, thiosemicarbazide. Shortly after, gabapentin was shown in vitro to reduce the release of the neurotransmitter dopamine from slices of rat caudate nucleus (striatum). This study provided evidence that the action of gabapentin, unlike baclofen, did not arise from the GABAB receptor. Initial clinical trials using small numbers of subjects were for treatment of spasticity and migraine but neither study had statistical power to allow conclusions. In 1987, the first positive results with gabapentin were obtained in a clinical trial using three dose groups versus pre-treatment seizure frequency for 75 days, as add-on treatment in patients who still had seizures despite taking other medications. Under the brand name Neurontin, it was first approved in the United Kingdom in May 1993, for the treatment of refractory epilepsy.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.